Two-Step Platform Technology
Pre Diagnostics is a pioneering diagnostics company focused on advancing precision medicine in AD and related neurodegenerative conditions.
Our core technology is designed to measure Aβ clearance efficiency in the blood by a two-step process consisting of:
1
Efficient isolation of blood monocytes
2
Detection of Aβ degradation using proprietary monoclonal antibodies that identify and quantify different Aβ fragments for specific cut-point sites of Aβ: aa-34, 20-aa, and aa-40/42
These PreADx biomarkers help to identify and quantify a dysfunctional Aβ clearance system - a key driver of AD and other neurodegenerative diseases.
Efficient isolation of blood monocytes
The PreDx technology has been optimized and automated to isolate monocytes from whole blood using a positive isolation method.
This approach employs antibodies selective for monocytes, which are bound to paramagnetic beads. When the sample is placed on a magnet, the bead-bound monocytes are efficiently separated from the rest of the blood components.
For intracellular analysis, the isolated cells can be lysed—disrupting the cell membranes and releasing their contents for further analysis. Using monocytes as the sample material allows for a higher concentration of biomarkers in the isolated fraction.
Combined with ultra-sensitive immunoassays (such as Simoa or MSD), this enables accurate detection of PreDx biomarkers, supporting improved disease categorization and personalized treatment strategies.
BloodCell-PreDx assay for
measuring Aβ degradation
efficiency
The BloodCell-PreDx assay consists of a whole blood culture system designed to measure key pathways of monocytic Aβ clearance efficiency—specifically, the uptake of Aβ1-40 and its degradation into smaller clearance fragments such as Aβx-34 or Aβ20-x over time. This assay is intended to reflect in vivo pathological processes associated with Alzheimer’s disease (AD) that are not captured by conventional biomarkers.
BloodCell-PreDx is a powerful tool for assessing additional aspects of neurodegeneration and ongoing neurovascular pathologies. As such, our technology enables better patient stratification and supports the selection of the most effective, personalized treatment for each individual.
Explore our pipeline
Diagnostics in development for Alzheimer’s and Parkinson’s disease
